---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Co-prescribed/Concomitant therapies. Topics: STOP-HAE: access to acute on-demand therapy; STOP-HAE: washout of long-term prophylaxis; Phase 1/2 study, HAE cohort: acute therapy and prior prophylaxis; Phase 3 extension study: access to acute therapy. 4 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### STOP-HAE: access to acute on-demand therapy

> “Able to use at least one acute therapy to treat HAE attacks (such as a plasma-derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

> “Access to acute medication(s) for attacks provided for all study participants”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-2.1.2.12-2"></a>

### STOP-HAE: washout of long-term prophylaxis

> “Have used any of the following for long-term prevention of HAE attacks: C1-INH agent (CINRYZE, HAEGARDA, RUCONEST) within 2 weeks prior to Screening.”
> “Berotralstat (ORLADEYO) within 3 weeks prior to Screening.”
> “Lanadelumab (TAKHZYRO) within 8 weeks prior to the Screening.”
> “Androgen use within 12 weeks prior to Screening.”
> “Received prior treatment with any RNA/DNA-based therapy for HAE or intolerant to any prior RNA/DNA-based therapy for any condition, excluding vaccines.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

> “In this trial, participants undergo a washout of previous long term prophylaxis treatment and then enter a 4-week screening window where baseline HAE attack rate is measured”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.12-3"></a>

### Phase 1/2 study, HAE cohort: acute therapy and prior prophylaxis

> “Participants must have access to, and the ability to use, acute medication(s) to treat angioedema attacks.”
> “Use of C1-INH products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis within four half-lives prior to screening”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-2.1.2.12-4"></a>

### Phase 3 extension study: access to acute therapy

> “Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
